MedTrace Logo

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

NCT01928030 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2017-03-21

Study results available
· View outcomes & findings →

Summary

This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.

Conditions

  • Lymphedema
  • Malignant Neoplasm

Interventions

BIOLOGICAL

recombinant human hyaluronidase

Given SC

Sponsors & Collaborators

Principal Investigators

  • Mark Pegram · Stanford University

  • Stanley Rockson · School of Medicine

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928030 on ClinicalTrials.gov